This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nickenig, G. Articles by Struijker-Boudier, H. Search for Related Content PubMed PubMed Citation Articles by Nickenig, G. Articles by Struijker-Boudier, H. Social Bookmarking                         What's this?

Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers

University of Saarland, Homburg, Germany

Jan Östergren

Karolinska University Hospital, Stockholm, Sweden, jan.ostergren@ karolinska.se

Harry Struijker-Boudier

University of Maastricht, Maastricht, The Netherlands

Targeting the renin-angiotensin-aldosterone system (RAAS), specifically the effector peptide angiotensin II (Ang II), represents a major opportunity for slowing the progression of cardiovascular disease (CVD) and, in turn, reducing the risk of morbidity and mortality. Inhibition of angiotensin-converting enzyme (ACE) and selective blockade of Ang II AT₁ receptors are two approaches through which the pathophysiological effects of Ang II can be targeted. Numerous clinical studies have established the benefits of ACE inhibitors P, (ACE-Is) in lessening the morbidity and mortality burden of CVD. There are, however, tolerability concerns associated with ACE-Is, such as angioedema and dry cough. By blocking Ang II at the AT₁ receptor level, Ang II receptor blockers (ARBs) provide a more specific and complete blockade of the deleterious effects of Ang II and tend to have more favourable tolerability. A number of clinical trials have shown that ARBs are not only associated with positive outcomes across the CVD continuum but may also have a role in the prevention or delay of diabetes (a major cardiovascular risk factor). Ongoing trials are aiming to define the place of such agents in lessening morbidity and mortality from CVD.

Key Words: Angiotensin II receptor blockers • Renin-angiotensin-aldosterone system • Cardiovascular disease continuum

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1 suppl, S1-S7 (2006)
DOI: 10.3317/jraas.2006.017


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?